Search for: "Alpha Art Materials, Co., Ltd." Results 1 - 4 of 4
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
New referral to the Enlarged Board by T 0438/19 - is product on the market prior art if undue burden to analyse composition? (G 1/13)
29 Jun 2023, 12:29 am by Roel van Woudenberg
The appellant argues that, owing to the absence of sufficient information on how to determine that amount, claim 1 lacks sufficiency of disclosure.2.1 It is undisputed that the presence of aluminium in the ethylene/alpha-olefin copolymer is taught to find its origin in the use of an organic aluminumoxy compound or organic aluminium compound added as co-catalyst for the polymerisation of the ethylene/alpha-olefin copolymer (page 4, lines 12-15 and paragraph 44 of the patent… [read post]
DeltaPatents EPO caselaw blog - http://dp-patentlaw.blogspot.nl/
Overreaching in patent claims dooms Gevo in district court. No infringement because of estoppel and invalidity through lack of enablement.
6 Aug 2013, 8:36 am by Lawrence B. Ebert
Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 535 U.S. 722, 122 S. [read post]
IPBiz - http://ipbiz.blogspot.com/
General Global Week in Review 13 June 2011 from IP Think Tank
13 Jun 2011, 4:14 am by Marie Louise
Ablaise Ltd. [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog
IP Think Tank Global Week in Review - 18 April 2008
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram) – Lundbeck wins… [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog